A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.
